GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

Indication for which reimbursement is requested

Latanoprost in combination with netarsudil can be used in adults with a certain type of glaucoma or with ocular hypertension (OHT). Glaucoma is a condition that damages the optic nerve. Without treatment, permanent loss of vision develops very slowly (after years). This is often due to high pressure in the eyeball. With OHT, the pressure in the eyeball is also too high, but the optic nerve is not yet damaged. The active substance latanoprost is already included as a separate component in the GVS for the treatment of glaucoma. 

Recommendations from the National Health Care Institute

The National Health Care Institute advises the Minister of VWS to include latanoprost/netarsudil on List 1B of the GVS.

Medicine Reimbursement System (GVS)

Latanoprost/netarsudil is an extramural drug. Extramural drugs are medicinal products for home use, available at the pharmacy on prescription from a physician. They will only be reimbursed from the basic health care package if they are listed in the GVS. The amount of the reimbursement depends on the list the product is on. Interchangeable medicinal products are clustered in List 1A. These may be subject to a reimbursement limit. Unique medicinal products are listed in List 1B. There is no reimbursement limit for these products. Additional conditions may apply for reimbursement. In that case, a medicinal product is also listed on List 2.

The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. Based on the assessment, the National Health Care Institute sends an advisory report to the Minister of Health, Welfare and Sport. The Minister makes the final decision whether or not to reimburse the medication from the basic health care package.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.